All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 59th American Society of Hematology Annual Meeting Atlanta, GA, USA, the AGP were delighted to attend a fascinating oral session, which was solely dedicated to biology, cytogenetics and molecular markers in diagnosis and prognosis for Acute Myeloid Leukemia (AML).
The session was co-chaired by Professor Aaron D. Goldberg, MD, PhD from the Memorial Sloan Kettering Center and Professor Francine E. Garrett-Bakelman, MD, PhD from the University of Virginia School of Medicine.
Daniel A. Pollyea from the University of Colorado Denver, Aurora, CO, gave a talk about the therapeutic value of the BCL-2 inhibitor, venetoclax (ven), in combination with azacitidine (aza) for elderly AML patients unfit for induction chemotherapy.
The speaker discussed the results of the phase Ib dose escalation/expansion study (NCT02203773) which combined aza at the standard dose and schedule, with ven daily in older AML patients who are not candidates for induction chemotherapy.
In total, 33 AML patients (median age = 75 years) were enrolled and received either 400 mg (n = 23), 800 mg (n = 9) or 1200 mg (n = 1) ven combined with a standard dose of aza. Two patients died of AML before the 7th day of the study.
Peripheral Blood Blasts (%) |
|||
---|---|---|---|
|
Pre-Treatment |
24 Hous Post-Treatment |
72 Hours Post-Treatment |
Patient 1 |
71% |
50% |
16% |
Patient 2 |
81% |
72% |
34% |
The speaker concluded that ven in combination with aza could be an effective and relatively safe alternative for untreated elderly AML patients who are not candidates for induction chemotherapy. He further added that this regimen can effectively target the leukemia stem cell population based on the depth and durability of responses. “LSCs can be specifically targeted by exploiting their metabolic vulnerabilities, this can translate into deep and durable remissions irrespective of traditional adverse risk factors for AML patients”.
Silke Kapp-Schwoerer from the University Hospital of Ulm, Ulm, Germany, presented results from a study which evaluated the clinical relevance of Nucleophosmin 1 mutated (NPM1mut) based Minimal Residual Disease (MRD) monitoring in patients with AML at high risk of relapse.
Bone Marrow (BM) and Peripheral Blood (PB) samples at diagnosis (BM [n = 3,527], PB [n = 2,812], after each treatment cycle (BM [n = 1,790], PB [n = 1,264]) and during follow-up (BM [n = 1,205], PB [1,163]) from 611 AML patients (age 18 to 60 years) who were enrolled in four German-Austrian AML Study group (AMLSG) trials (NCT00146120, NCT00151242, NCT00893399, NCT01477606) were analysed in this study. Patients were treated with idarubicin, cytarabine and etoposide (ICE) as double induction +/- ATRA or GO, or one induction cycle with daunorubicin and cytarabine followed by one to four cycles of high dose cytarabine (n = 363, 59%), or autologous (n = 19, 3%) or allogenic (n = 162, 27%) Hematopoetic Stem Cell Transplantation (HSCT). Sixty-seven patients did not complete/receive consolidation. Median follow-up was 3.2 years. NPM1mut transcript ratio (NPM1mut/ABL1 transcripts x 104) were determined using cDNA based RQ-PCR.
In summary, NPM1mut MRD assessment in the BM after two treatment cycles was highly informative and identified patients at an increased risk of relapse. Additionally, the study revealed that RQ-PCRneg in the BM and PB is an independent factor for better OS and longer remission duration. After two treatment cycles, achievement of RQ-PCR negativity in both, the BM and the PB samples, was significantly associated with a lower CIR, independent of concurrent FLT3-ITD and DNMT3A mutation status while superior OS was only seen for the BM samples. The FLT3-ITD/DNMT3Amut genotype impacted on reduction of NPM1mut transcript levels and achievement of RQ-PCR negativity. Furthermore, during follow-up, transcript levels above > 200 were highly predictive for relapse in both BM and PB samples.
The next talk during this session was given by Patrick Williams, from the University of Texas MD Anderson Cancer Center, Houston, TX, USA. The speaker presented results from a study which investigated how AML suppresses immune responses by expressing cytokines and immune checkpoint ligands as well as drafting suppressive immune cells like regulatory T cells (Tregs).
BM aspirates from 107 patients with newly diagnosed (n = 39) or relapsed (n = 68) AML were analysed by 17 color flow-cytometry assay. The authors evaluated the expression of inhibitory (PD1, CTLA4, LAG3, TIM3) and stimulatory receptors (GITR, OX40, 41BB, ICOS) on T cell subsets: CD4 T effector cells (Teff): CD3+CD4+CD127lo/+Foxp3-, CD4 T regulatory cells (Treg): CD3+CD4+CD127-Foxp3+, and CD8 T cells and the expression of their ligands (41BBL, B7-1, B7-2, ICOSL, PDL1, PDL2 and OX40L) on AML blasts. Eight healthy donor BMs were used as controls.
The speaker concluded, that the increased Treg and PD1+ CD8 T cell infiltration and the increased PD1+TIM3+ and PD1+LAG3+ CD8 T cells in the BM of patients with AML “indicates immune suppression at multiple levels”. He further added that the “dual contributions by T cells and blasts to immune suppression” suggests that these pathways may play a crucial role in AML patient survival and thus may benefit from immune checkpoint therapy.
The final talk of the session was presented by Ann-Kathrin Eisfeld, from the Ohio State University, Division of Hematology, Columbus, OH, USA.
During this talk, the speaker presented results from a study which aimed to assess the frequency, clinical and molecular associations and the possible prognostic impact of the Neurofibromin 1 gene (NF1) mutations in AML.
In this study, targeted mutation assessment was performed in 1,021 adult patients with de novo AML aged either < 60 years (n = 690) or ≥ 60 years (n = 331) and were treated on a Cancer and Leukemia Group B/Alliance for Clinical Trials in Oncology protocols. Overall, 81 cancer- and leukemia-associated genes were analysed using costume-designed targeted next-generation sequencing panels (Miseq), moreover, bi-allelic CEBPA mutation status was assessed by Sanger sequencing resulting in a total of 82 analysed genes. The mutated genes were assigned to nine previously described functional groups defined based on the genes' biologic functions as follows: NPM1, methylation-related, splieceosome, kinases, transcription factors, RAS, chromatin remodelling, cohesion complex, tumor suppressors.
In summary, these findings established that NF1 belongs to the 20 most frequently mutated genes in adult AML, occurring in 5.1% of patients. Additionally, the findings of this study suggests that NF1 mutation is associated with adverse prognostic outcomes in AML patients treated with standard chemotherapy. NF1-mutated patients aged ≥60 have lower CR rates compared to NF1 wild-type patients.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox